Rohto Pharmaceutical, Mitsui & Co. to Acquire Singapore-Based Eu Yan Sang — Update
By Kosaku Narioka
Rohto Pharmaceutical and Mitsui & Co. plan to acquire Singapore-based Chinese herbal medicine company Eu Yan Sang International in a deal that values the company at 800 million Singapore dollars (US$593.5 million).
Rohto said Thursday that an entity funded by the company and Mitsui would acquire an 86% stake in Eu Yan Sang from Singapore-based Righteous Crane Holding and start a tender offer for the remaining 14% stake thereafter.
Following the transactions, Rohto plans to hold about 60% of the traditional Chinese medicine company, Mitsui would hold about 30% and the founding family of Eu Yan Sang about 10%, Rohto said.
Founded in 1879, Eu Yan Sang manufactures and sells traditional Chinese medicines, operating more than 170 stores and 30 herbal medicine clinics mainly in Singapore, Hong Kong and Malaysia.
Rohto said it aimed to realize an innovative health business by combining Eu Yan Sang's strong product portfolio and brand reputation in Asia with its research, development and sales capabilities.
Righteous Crane is owned by a Tower Capital Asia fund, a unit of Singapore's Temasek Holdings and certain members of the founding family.
Mitsui invested in Eu Yan Sang through a fund in November 2022. Upon the stake acquisition, the fund will be liquidated and Mitsui will re-invest in the Chinese herbal medicine company through the entity jointly funded by Rohto, the companies said.
The stake acquisition is expected to be completed around June 30, they said.
Deutsche Bank and UBS are acting as financial advisers to Eu Yan Sang.
Write to Kosaku Narioka at kosaku.narioka@wsj.com
(END) Dow Jones Newswires
April 04, 2024 06:07 ET (10:07 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
10 Top-Performing Dividend Stocks of the Month
-
Marathon Petroleum Earnings: No Change to Competitive Position, but Shares Look Expensive
-
Charlie Munger and How Not to Invest
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
After Earnings, Is AT&T Stock a Buy, a Sell, or Fairly Valued?
-
Mastercard Earnings: A Stable Environment Highlights the Firm’s Strengths
-
Pfizer Earnings: Solid Results Supported by Steady Tracking Toward $4 Billion In Cost Cuts
-
Starbucks Earnings: Not a Lot to Like About Results as Global Traffic Sputters